Skip to main content

Table 1 Baseline clinical characteristics of the study participants with or without atrial fibrillation

From: Elevated plasma Ninjurin-1 levels in atrial fibrillation is associated with atrial remodeling and thromboembolic risk

  Control AF P value
Number 51 96
AF history, years - 4.35 ± 6.51
Male (%) 21 (41.18%) 56 (58.33%) 0.057
HTN (%) 26 (50.98%) 58 (60.42%) 0.297
DM (%) 7 (13.73%) 26 (27.08%) 0.096
CAD (%) 2 (3.92%) 10 (10.42%) 0.218
Smoking (%) 15 (29.41%) 17 (17.71%) 0.141
Drinking (%) 12 (23.53%) 16 (16.67%) 0.378
Age, years 65.00 (55.00, 68.00) 66.00 (60.00, 72.00) 0.039*
BMI, kg/m2 26.23 ± 3.32 25.68 ± 3.27 0.411
WBC, × 109/L 6.31 ± 1.19 6.05 ± 1.43 0.417
HGB, g/L 129.65 ± 14.69 138.77 ± 16.30 0.016*
PLT, × 109/L 221.78 ± 43.40 201.92 ± 60.16 0.139
TC, mmol/L 4.05 ± 0.95 4.05 ± 0.89 0.986
TG, mmol/L 1.08 (0.88, 1.81) 1.18 (0.88, 1.49) 0.873
LDL-C, mmol/L 2.52 ± 0.85 2.62 ± 0.87 0.519
HDL-C, mmol/L 1.19 ± 0.29 1.09 ± 0.32 0.079
AST, U/L 18.55 ± 5.78 20.43 ± 7.49 0.159
ALT, U/L 16.00 (12.25, 20.95) 17.00 (13.25, 23.00) 0.544
sCr, μmol/L 67.48 ± 14.55 70.97 ± 15.01 0.215
cTNI, ng/mL 0.00 (0.00, 0.01) 0.00 (0.00, 0.01) 0.662
HbA1c (%) 5.90 (5.70, 6.20) 5.90 (5.70, 6.55) 0.921
LVEF (%) 68.38 ± 5.20 64.28 ± 6.67 0.001**
LAVI, ml/m2 19.16 (15.08, 21.83) 26.90 (19.83, 32.27) < 0.001***
ESR, mm/h 4.00 (2.50, 9.50) 4.00 (2.00, 8.00) 0.460
  1. Data are presented as mean ± SD, median (quartile) or number (%). ALT, alanine aminotransfease; AST, aspartate aminotransferase; BMI, body mass index; cTNI, cardiac troponin I; CAD, coronary artery disease; DM, diabetes mellitus; ESR, erythrocyte sedimentation rate; HTN, hypertension; HDL-C, high density lipoprotein cholesterol; HGB, hemoglobin; HbA1c, hemoglobin A1c; LDL-C, low density lipoprotein cholesterol; LVEF, left ventricular ejection fraction; LAVI, left atrial volume index; PLT, platelet; sCr, serum creatinine; TC, total cholesterol; TG, triglyceride; WBC, white blood cell
  2. *P < 0.05; **P < 0.01; ***P < 0.001